
Although zzso has been an attractive term for zzso and patients, zzso really want to know which therapy to start for a given patient and when to zzso that therapy in favor of an zzso In efficacy trials, cancer zzso have conventionally been assessed by zzso that are based on the zzso Response zzso zzso In Solid zzso zzso zzso In this article, we make the case for a new paradigm in which zzso are assessed on a continuous scale by evidence of zzso using a variety of quantitative tools that take advantage of zzso innovations and increasing understanding of cancer zzso The new paradigm relies on zzso comparisons between zzso arms and control arms, as historical controls are unavailable or unreliable for these quantitative zzso We discuss multiple limitations of zzso including its zzso on tumor regression, concerns about the accuracy of tumor zzso and the zzso of comparisons with historical controls, and its zzso in disease settings in which tumor zzso on zzso imaging are difficult or zzso We discuss how the new paradigm overcomes these limitations and provides a framework for answering the key questions of the zzso and improving patient zzso 

